Filtered By:
Management: Marketing

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 200 results found since Jan 2013.

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research

Health News: Believe it or Not
Vitamin D Deficiency May Cause MS Employees Working Long Hours Face Increased Risk of Stroke Coffee Could Literally be a Lifesaver When you see these health headlines do you immediately think of how it pertains to you or someone you know?  You probably don’t think, “I should make sure this information is from a reputable source,” or “I should read that research article that this information is based on and ask my clinician about it.” Health care reporting is complicated and has its challenges.  Many journalists do not have the background or education in health and science and are just as uni...
Source: Dragonfly - December 11, 2015 Category: Databases & Libraries Authors: Carolyn Martin Tags: Health Literacy/Consumer Health Source Type: news

Can You Think Yourself Into A Different Person?
For years she had tried to be the perfect wife and mother but now, divorced, with two sons, having gone through another break-up and in despair about her future, she felt as if she’d failed at it all, and she was tired of it. On 6 June 2007 Debbie Hampton, of Greensboro, North Carolina, took an overdose of more than 90 pills – a combination of ten different prescription drugs, some of which she’d stolen from a neighbor’s bedside cabinet. That afternoon, she’d written a note on her computer: “I’ve screwed up this life so bad that there is no place here for me and nothing I can contr...
Source: Science - The Huffington Post - November 19, 2015 Category: Science Source Type: news

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their ...
Source: Therapeutic Advances in Neurological Disorders - October 27, 2015 Category: Neurology Authors: Safouris, A., Triantafyllou, N., Parissis, J., Tsivgoulis, G. Tags: Reviews Source Type: research

Silk Road Medical Announces up to $57 Million in New Funding for Novel Approach to Preventing Strokes
Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure SUNNYVALE, Calif., Oct. 20, 2015 -- (Healthcare Sales & Marketing Network) -- Silk Road Medical, Inc., a company dedicated to a... Devices, Interventional, Venture CapitalSilk Road Medical, Transcarotid Neuroprotection, Transcarotid Stent, stroke
Source: HSMN NewsFeed - October 20, 2015 Category: Pharmaceuticals Source Type: news

No, Omega 3-Enriched Beef Is Not Necessarily Heart Healthy
Feeding cattle flaxseed or marine algae can raise the omega-3 fatty acid levels in ground beef from 30 milligrams per serving to 200 milligrams per serving, as Kansas State University researchers have found. But do higher levels of omega-3s make red meat significantly healthier?   Not according to Kim Larson, a registered dietitian nutritionist and spokesperson for the Academy of Nutrition and Dietetics. The attempt to make beef look like an important source of omega-3s is essentially a marketing ploy, she said. And despite the fatty acid's reputation as a health ...
Source: Science - The Huffington Post - October 14, 2015 Category: Science Source Type: news

South Carolina Is FED UP
When asked to speak for a group of third and fourth graders about making "healthy choices," I picked the topic that most children have in common ... sugar! I began our discussion with one simple question. "If your parents came into the room and saw you eating out of the sugar bowl, what would they say?" One young man stated it best. "Are you crazy? Put that spoon down!" "Why would your parents say that?" I asked. Another little girl could barely contain herself. Waving her hand furiously she blurted out, "Because all that sugar is bad for you!" Out of the mouths of babes. When I talk to children, teens or adults,...
Source: Healthy Living - The Huffington Post - September 17, 2015 Category: Consumer Health News Source Type: news

7 Ways to Avoid Death Via the Rat Race
In case you haven't figured it out, the rat race is real, and it can be very dangerous to your health and soul. Whether you work for someone or own a small business and work for multiple clients, chances are you have felt the weight of the rat race. We live in a 24/7 world with access to our work at all moments of day. Unfortunately, the first thing that many of us do in the morning is check our phones and enter a never ending stream of data. In Japan, death by overwork is a very real problem. According to Economy Watch, thousands of workers die each year after working too much work, and the government is stepping in to c...
Source: Healthy Living - The Huffington Post - September 4, 2015 Category: Consumer Health News Source Type: news

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer’s Xarelto® in Patients with Non-Valvular Atrial Fibrillation (for specialized target groups only)
Insights from more than 45,000 real-world patients with atrial fibrillation (AF) confirm low bleeding rates for Xarelto / Late-breaking XANTUS study expands on ROCKET AF data, demonstrating Xarelto provides highly effective stroke prevention in both high- and lower-risk patients / Two-year findings from an ongoing post-marketing safety surveillance (PMSS) study show rates and patterns of major bleeding to be consistent with ROCKET AF
Source: Bayer Company News - September 1, 2015 Category: Pharmaceuticals Source Type: news

McGuire to take reins at Second Sight, Greenberg heads board | Personnel Moves
Second Sight Medical‘s (NSDQ:EYES) newly appointed CEO Will McGuire is set to take the reins starting August 18, the company said. Announced in June, former CEO Dr. Robert Greenberg will become chairman of the board at Second Sight, replacing Alfred Mann who will become chairman emeritus, according to the Sylmar, Calif.-based ‘bionic eye’-developing company. “Will brings an immense depth of experience in the life sciences industry that will advance Second Sight’s commercialization of the Argus II retinal prosthesis. After a thorough search process, management and the board of directors are con...
Source: Mass Device - August 13, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Invuity Monteris Medical Personnel Moves Second Sight Medical Products Inc. Volcano Corp. Source Type: news

Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes
Abstract Atrial fibrillation is the most common arrhythmia and is associated with significant morbidity and mortality. The current therapeutic options for patients at high thromboembolic risk include the vitamin K antagonists and the direct oral anticoagulants. These novel agents have been evaluated in more than 40,000 patients enrolled in four large randomized controlled trials for stroke prevention in non-valvular atrial fibrillation. When these results were pooled together, a greater efficacy profile, as well as a consistent reduction in life-threatening bleeding was shown in comparison to vitamin K antagonists...
Source: Internal and Emergency Medicine - July 7, 2015 Category: Emergency Medicine Source Type: research

Smoking Rates Are Down, But A Different Type Of Tobacco Use Is On The Rise
First, the good news: Smoking rates are down significantly in 26 states. The bad news? The use of smokeless tobacco (also known as dip, snuff or chew) is up in four states, while using both cigarettes and smokeless tobacco is up significantly in five states. “Although overall cigarette smoking prevalence has declined significantly in recent years in many states, the overall use of smokeless tobacco and concurrent cigarette and smokeless tobacco has remained unchanged in most states and increased in some states,” summed up researchers for the Centers for Disease Control, which published the data in their weekly Morbid...
Source: Science - The Huffington Post - May 22, 2015 Category: Science Source Type: news

Thrombolysis in acute ischaemic stroke - time for a rethink?
In the US the licence, or marketing authorisation, for alteplase is limited to 0-3 hours after onset of stroke, but some other countries - including the UK and Australia - have extended the licence to 4.5 hours. In an analysis article on thebmj.com Brian Alper, vice president of evidence based medicine research and development at Dynamed, and colleagues, interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours. Read their full analysis: http://www.bmj.com/content/350/bmj.h1075
Source: The BMJ Podcast - March 18, 2015 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts

Boston Scientific Receives FDA Approval for WATCHMAN(TM) Left Atrial Appendage Closure Device
First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation MARLBOROUGH, Mass., March 13, 2015 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE:... Devices, Cardiology, FDABoston Scientific, WATCHMAN Device, Left Atrial Appendage Closure Device
Source: HSMN NewsFeed - March 16, 2015 Category: Pharmaceuticals Source Type: news